BioSpace News Archive

NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27, 2020 at 11:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website, www.abeonatherapeutics.com

Stryker announced that Stryker B.V., an indirect, wholly owned subsidiary of Stryker, has extended the offering period of its previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V.

NEW YORK , Feb. 26, 2020 /PRNewswire/ -- Primary endpoints successfully met Results confirm significant clinical benefits of ORMD-0801 at lower dose treatment 0.95% (0.81% placebo adjusted) A1C reduction in patients treated once daily at 8mg Excellent safety profile Paves the way for FDA discussions on Phase 3 Study Confere

CRANFORD, N.J. , Feb. 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the Third Annual LD Micro Virtual Conference on Wednesday, March 4, 2020 at 11 AM ET . Event: Thir

FREMONT, Calif , Feb. 26, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx, will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET on Wednesday , March 4, 2020 in Boston, MA. To access the live webcast of Ardelyx’s

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Cowen and Company 40th Annual Health Care Conference in Boston, MA, on Wednesday, March 4 at 9:20 a.m. Eastern Time

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Extension Protocol to the Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C1 (NPC1) patients.

Feb. 26, 2020 13:00 UTC scPharmaceuticals Inc. to Present at the Cowen and Company’s 40 th Annual Health Care Conference BURLINGTON, Mass.--( BUSINESS WIRE )-- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that John Tucker, president and chief executive officer, will present at

Feb. 26, 2020 13:00 UTC BRISBANE, Calif.--( BUSINESS WIRE )-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will present at two upcoming investor conferences in March: Event: The 40 th Annual Cowen Health Care Conference Date: Tuesday, March 3, 2020 Presentation Time: 9:20 a.m. ET Location:

Feb. 26, 2020 13:00 UTC Alnylam Announces Approval in Brazil of ONPATTRO ® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy − ONPATTRO is the First-Ever RNAi Therapeutic Approved in Latin America – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved ONPATTRO ® (patisiran) for the treatment of heredita